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Overweight and obesity are important risk factors for a number of diseases that have a significant and increasing 
global burden.1,2 These diseases include 
type 2 diabetes,3 ischaemic heart disease,4 
cerebrovascular disease5 and some cancers,6 
with risks increasing proportionate to body 
mass index (BMI).7 Overweight and obesity 
are also notable risk factors for a range of 
other conditions including osteoarthritis8 
and depression,9 and other risk factors 
with a significant global burden such as 
hypertension and high blood glucose.1 
Further, the healthcare costs of overweight 
and obesity are significant. The most recent 
estimates for Australia (2014–15) indicate that 
governments spend an additional $AU2.6 
billion on healthcare costs each year due to 
obesity (BMI ≥ 30 kg·m-2).10
In high-income countries, a higher prevalence 
of obesity is observed among those with 
greater socioeconomic disadvantage.11 This 
socioeconomic gradient of obesity is likely 
to contribute to socioeconomic inequalities 
in morbidity and mortality.12 In Australia, 
as elsewhere, greater socioeconomic 
disadvantage is also associated with a higher 
risk of a wide range of disease outcomes, 
including those associated with obesity 
as described above.11,13 For example, 
Australian adults residing in areas of greatest 
socioeconomic disadvantage have a 1.8-
fold higher rate of ischaemic heart disease 
mortality compared to their counterparts in 
areas of least socioeconomic disadvantage.14
One study has estimated the proportion 
of kidney cancer, colorectal cancer, breast 
cancer, diabetes mellitus, ischaemic heart 
disease, cerebrovascular disease and all-
cause mortality attributable to educational 
differences in overweight and obesity for 21 
European populations.15 To our knowledge, 
how this translates to the absolute number of 
deaths and incident cases of disease, and the 
implications of this for direct healthcare costs, 
has never been quantified. Reducing the 
socioeconomic gradient in overweight and 
obesity will require concerted public health 
action to research and implement equitable 
prevention and treatment initiatives across 
the socioeconomic gradient. Understanding 
the burden of disease and healthcare costs 
attributable to socioeconomic differences 
in overweight and obesity, overall and for 
different socioeconomic groups will galvanise 
support for action.
The aim of this study was to estimate the 
annual burden of disease (through key 
disease outcomes and all-cause mortality) 
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Abstract
Objective: We aimed to quantify the extent to which socioeconomic differences in body mass 
index (BMI) drive avoidable deaths, incident disease cases and healthcare costs. 
Methods: We used population attributable fractions to quantify the annual burden of disease 
attributable to socioeconomic differences in BMI for Australian adults aged 20 to <85 years 
in 2016, stratified by quintiles of an area-level indicator of socioeconomic disadvantage 
(SocioEconomic Index For Areas Indicator of Relative Socioeconomic Disadvantage; SEIFA) and 
BMI (normal weight, overweight, obese). We estimated direct healthcare costs using annual 
estimates per person per BMI category.
Results: We attributed $AU1.06 billion in direct healthcare costs to socioeconomic differences 
in BMI in 2016. The greatest number (proportion) of cases and deaths attributable to 
socioeconomic differences in BMI was observed for type 2 diabetes among women (8,602 total 
cases [16%], with 3,471 cases [22%] in the most disadvantaged quintile [SEIFA 1]) and all-cause 
mortality among men (2027 total deaths [4%], with 815 deaths [6%] in SEIFA 1). 
Conclusions: Socioeconomic differences in BMI substantially contribute to avoidable deaths, 
disease cases and direct healthcare costs in Australia. 
Implications for public health: Population-level policies to reduce socioeconomic differences 
in overweight and obesity must be identified and implemented.
Key words: socioeconomic factors, obesity, body mass index, epidemiology, epidemiological 
monitoring, costs and cost analysis
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and direct healthcare costs attributable to 
the unequal distribution of overweight and 
obesity across the socioeconomic gradient for 
Australian adults in 2016.
Methods
Study design
To estimate the unequal distribution of 
overweight and obesity, we compared the 
2016 prevalence of overweight and obesity for 
Australian women and men across quintiles of 
socioeconomic disadvantage (observed; data 
modelled from the 2014–15 National health 
Survey16) with the prevalence of overweight 
and obesity that would be expected to occur 
if all quintiles of socioeconomic disadvantage 
had the same prevalence of overweight and 
obesity as the women and men in the least 
disadvantaged quintile (counterfactual). 
Comparing this observed and counterfactual 
prevalence of overweight and obesity allows 
us to estimate the disease burden and direct 
healthcare costs attributable to the unequal 
distribution of overweight and obesity for 
Australian women and men. 
We used the SocioEconomic Index for Areas 
(SEIFA), ‘index of relative socioeconomic 
disadvantage’ to indicate the level of 
socioeconomic disadvantage. SEIFA 
is an ordinal, area-based indicator of 
socioeconomic position that reflects the 
average socioeconomic characteristics 
of residents within each of the 54,805 
statistical geographic areas in Australia (each 
containing approximately 400 individuals) 
based on Census information,17 and ranks 
them from most to least disadvantaged. 
We used quintiles of SEIFA, whereby SEIFA 
1 represents residents living in areas with 
greatest socioeconomic disadvantage, and 
SEIFA 5 represents residents living in areas 
with least socioeconomic disadvantage. 
To estimate the annual disease burden, we 
selected eight key obesity-related disease 
outcomes – outcomes that were both 
strongly associated with obesity18 and 
represent a significant global burden.2 This 
included three cardio-metabolic diseases: 
type 2 diabetes, ischaemic heart disease 
and cerebrovascular disease; four cancers: 
colorectal cancer, kidney cancer, endometrial 
cancer and post-menopausal breast cancer; 
and all-cause mortality. Where Australian 
data were available, we examined both 
incidence (number of cases) and mortality 
(number of deaths) for each disease outcome 
(Supplementary Tables 1 and 2). 
All disease inputs were sex-specific and 
derived for Australian adult women and men 
aged 20 to <85 years (or women 50 to <85 
years for post-menopausal breast cancer) 
according to quintiles of SEIFA. We used the 
most recently available Australian data for 
each input (which ranged from 2000–2012 to 
2016; Supplementary Table 1) and weighted 
all estimates to the 2016 population size 
of women and men aged 20 to 84 years.19 
As Australian data for most inputs were 
not available disaggregated by SEIFA for 
the 20 to 84 years age group, multiple data 
sources were combined to estimate the 
age- and SEIFA-specific input data for this 
analysis (Supplementary Table 2). A detailed 
description of how datasets were combined 
for each input is described in Supplementary 
File A.
To calculate the population attributable 
fractions (PAFs; described below), we used a 
sex-specific relative risk, rate ratio or hazard 
ratio (RR) for the relationship between 
overweight and obesity and each disease 
outcome, relative to normal weight, from the 
most contemporary, or most comprehensive, 
meta-analysis of cohort studies, or pooled 
cohort analysis (Supplementary Table 3). In 
line with previous research,2 where possible 
we used RRs that were adjusted for key 
confounders (including age, sex, smoking 
status) and did not adjust for factors likely 
to lie within the causal pathway between 
obesity and the disease (such as diet and 
physical activity). We use the same RRs for 
all SEIFA quintiles, thereby assuming that 
SEIFA does not moderate the relationship 
between obesity and disease outcomes (this 
assumption has been empirically validated in 
a prior Australian study for type 2 diabetes).20
Analyses 
As per Hoffman et al.21 we used sex-specific 
population attributable fractions (PAF) 
to estimate the proportion of deaths and 
incident cases attributable to the unequal 
distribution of normal weight (NW) 
overweight (OW) and obesity (Ob): PAF = 
[(RR Ob * %Ob observed + RR OW* %OW observed + 1 
* %NW observed) – (RR Ob * %Ob counterfactual + RR 
OW* %OW counterfactual + 1 * %NW counterfactual)]/
(RR Ob * %Ob observed + RR OW* %OW observed + 
1 * %NW observed). We calculated an estimate 
range of the PAF for each disease outcome 
by repeating the calculation using the upper 
and lower 95%CI estimates of the RR. For each 
disease outcome, we multiplied the PAF by 
the observed number of deaths and incident 
cases to estimate the annual number of 
deaths and cases potentially attributable to 
the unequal distribution of overweight and 
obesity. 
We used a relative concentration index 
(RCI) and absolute concentration index 
(ACI) to assess the overall magnitude of 
relative inequality and absolute inequality 
for each disease outcome attributable to 
the unequal distribution of overweight 
and obesity. Here, negative RCI and ACI 
values indicate a disproportionate share of 
each disease outcome among those with 
greater socioeconomic disadvantage, a 
value of 0 for the RCI and ACI indicates no 
inequality, and positive RCI and ACI values 
indicate a disproportionate share of each 
disease outcome among those with lesser 
socioeconomic disadvantage.
To estimate the direct healthcare costs 
attributable to the unequal distribution 
of overweight and obesity across the 
socioeconomic gradient, we used previously 
derived estimates of the annual direct 
healthcare costs per person from a cohort 
of Australian adults that was broadly 
representative of the Australian population.31 
These estimates were applied to the average 
observed and counterfactual prevalence of 
normal weight, overweight and obesity for 
Australian women and men aged 20 to 84 
years in 2016. Costs were inflated from 2005 to 
2016 Australian dollars using historical Health 
Price indices and linear trend estimation.22
All analyses were sex-specific and conducted 
for Australian adults aged 20 to 84 
years in 2016 (or 50 to 84 years for post-
menopausal breast cancer). Input data16,19-44 
is described in full in Supplementary File A 
and Supplementary Tables 1, 2 and 3. The 
statistical methodology is described in detail 
in Supplementary File B.
Ethics statement
Ethics approval for the current study was 
obtained through the Monash University 
Human Research Ethics Committee; CF15/21 
– 2015000018, and through Deakin University 
Human Research Ethics Committee; 2016-
0141.
Results
SEIFA-patterning of normal weight, 
overweight and obesity 
For women, we observed a socioeconomic 
gradient in the prevalence of obesity and 
normal weight across SEIFA quintiles. 
Compared to women with greatest 
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socioeconomic disadvantage (SEIFA 
1), women with least socioeconomic 
disadvantage (SEIFA 5) had a 14%-point 
higher prevalence of normal weight, and 
a 12%-point lower prevalence of obesity 
(Figure 1, Supplementary Table 4). We did 
not observe a socioeconomic gradient in the 
prevalence of overweight, which varied by up 
to 4%-points across all SEIFA quintiles.
For men, we observed a socioeconomic 
gradient in the prevalence of obesity, 
overweight and normal weight. Compared 
to men with greatest socioeconomic 
disadvantage (SEIFA 1), men with least 
socioeconomic disadvantage (SEIFA 5) had a 
5%-point higher prevalence of normal weight, 
a 8%-point higher prevalence of overweight, 
and a 13%-point lower prevalence of obesity 
(Figure 1, Supplementary Table 4). 
SEIFA-patterning of each disease 
outcome
With the exception of incident post-
menopausal breast cancer, those with 
greater socioeconomic disadvantage had 
higher rates of each disease and all-cause 
mortality compared to their counterparts 
with lesser disadvantage (Table 1). This was 
reflected by a negative RCI and ACI (Figure 
2). The socioeconomic patterning of post-
menopausal breast cancer was not clear. 
The highest incidence was observed for 
women with second greatest socioeconomic 
disadvantage (SEIFA 2), followed by women 
with least socioeconomic disadvantage 
(SEIFA 5), and then women with greatest 
socioeconomic disadvantage (SEIFA 1). This 
was reflected by an observed RCI of -0.006. 
The RCI and ACI for all outcomes was 
improved under the counterfactual 
distribution of overweight and obesity 
(values were closer to 0, indicating less 
inequality), but remained negative (indicating 
a disproportionate share of disease 
among those with greater socioeconomic 
disadvantage); see Figure 2. 
Disease burden attributable to the 
unequal distribution of overweight 
and obesity
We present in Table 2, for each SEIFA quintile 
and all quintiles together, the proportion of 
each disease outcome potentially attributable 
to differences in the prevalence of overweight 
and obesity across the socioeconomic 
gradient (PAF), as well as the estimated 
number of cases or deaths this equates to.
Figure 1. Age-standardised observed and counterfactual prevalence of normal weight, overweight and obesity for 
Australian women and men aged 20 to 84 years in 2016.
Notes:
All estimates were age-standardised to the SEIFA-specific 2016 population using the direct method; NW, Normal weight (BMI<25 kg m-2); OW, Overweight 
(BMI≥25 kg m-2 and <30 kg m-2); OB, Obese (BMI≥30 kg m-2); W, Women; M, Men; SEIFA, Socioeconomic index for areas, ‘index of relative socioeconomic 
disadvantage’, where SEIFA 1 represents residents of areas with greatest socioeconomic disadvantage, and SEIFA 5 represents residents of areas with least 
socioeconomic disadvantage; The counterfactual distribution reflects the prevalence of normal weight, overweight and obesity that would be expected to occur 
if all SEIFA quintiles had the same prevalence of normal weight, overweight and obesity as the women and men in the least disadvantaged quintile.
The greatest number of incident cases 
attributable to socioeconomic differences in 
BMI was observed for type 2 diabetes among 
women (8,602 cases [16%]), with 3,471 cases 
[22%] in the most disadvantaged quintile 
[SEIFA 1]). The greatest number of deaths 
attributable to socioeconomic differences 
in BMI was observed for all-cause mortality 
among men (2,027 deaths [4%], with 815 
deaths [6%] in SEIFA 1).
In total: 16,281 cases of type 2 diabetes, 
colorectal cancer, kidney cancer, endometrial 
cancer and post-menopausal breast cancer; 
3,562 deaths from all-cause mortality; and 
596 deaths from ischaemic heart disease, 
cerebrovascular disease, colorectal cancer, 
kidney cancer, endometrial cancer and 
post-menopausal breast cancer could be 
attributed to the socioeconomic gradient in 
overweight and obesity among Australian 
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that used a PAF model to calculate the 
burden of educational differences in the 
prevalence of overweight and obesity 
on mortality from three cancers (kidney 
and renal pelvis cancer, post-menopausal 
breast cancer and colorectal cancer), three 
cardio-metabolic diseases (ischaemic heart 
disease, cerebrovascular disease and diabetes 
mellitus), and all-cause mortality across 21 
European countries.15 Across the two studies, 
PAF estimates for women differ by up to 
1.5%-points, and PAF estimates for men differ 
by up to 3%-points.
Australia is not unique in having both a 
high prevalence of overweight and obesity 
and a steep socioeconomic gradient in 
both overweight and obesity and disease 
outcomes of interest. As demonstrated 
through the similarity of our PAF estimates 
and a prior study,15 the proportion of the 
disease burden described for Australian 
adults may be comparable to the proportion 
of the disease burden for other high-income 
countries. 
We are the first to estimate the direct 
healthcare costs that can be attributed to 
the unequal distribution of overweight 
and obesity across socioeconomic groups. 
Our findings support previous studies that 
have demonstrated a significant potential 
economic benefit to reducing racial 
inequalities in disability, illness and premature 
mortality in the US,45 health inequalities 
by income level in Canada46 and general 
socioeconomic inequalities in the UK.47 
Strengths and limitations
The first strength of this study is our use 
of a robust and systematic approach21 to 
model the disease burden associated with 
the unequal distribution of overweight and 
obesity across the socioeconomic spectrum. 
We examine both all-cause mortality and 
key disease outcomes with a high burden. 
Additionally, we examine both the proportion 
and absolute number of deaths and cases of 
key diseases and all-cause mortality that can 
be attributed to the socioeconomic gradient 
in overweight and obesity. 
Secondly, the data for our model inputs 
included measured height and weight and 
ICD-10 coded disease outcomes. Further, 
unlike previous studies, we model incident 
type 2 diabetes, which is more strongly 
associated with overweight and obesity than 
diabetes mellitus (a combined estimate of 
type 1 and type 2 diabetes). This ensures our 
Table 1. Observed number of deaths and incident cases of disease for Australian adults aged 20 to 84 years in 2016.
SEIFA 1 SEIFA 2 SEIFA 3 SEIFA 4 SEIFA 5
N N N N N
All-cause mortality
W 9,212 8,910 7,639 6,600 6,261
M 13,737 12,966 11,250 11,189 8,122
Incident type 2 diabetes
W 15,961 10,784 12,499 8,910 7,049
M 18,791 15,839 10,601 12,301 12,093
Ischaemic heart disease mortality
W 778 751 633 539 507
M 1,858 1,712 1,477 1,158 1,019
Cerebrovascular disease mortality
W 537 543 460 400 420
M 590 563 492 398 388
Colorectal cancer incidence and mortality
W I 1,249 1,275 1,142 1,107 1,070
W M 304 295 266 242 232
M I 1,677 1,712 1,554 1,388 1,314
M M 449 424 401 332 307
Kidney cancer incidence and mortality
M I 407 434 396 356 341
M 112 114 104 80 73
Endometrial cancer incidence and morality
W I 512 533 486 468 434
M 87 93 88 75 69
Post-menopausal breast cancer incidence and mortality (Aged 50 to <85 years)
W I 2,649 2,757 2,544 2459 2,703
M 482 456 410 357 368
Notes:
SEIFA, Socioeconomic index for areas, ‘index of relative socioeconomic disadvantage’
W: women; 
M: men 
women and men in 2016. Further, we 
found that the socioeconomic gradient in 
overweight and obesity contributes to the 
relative and absolute inequalities for each 
disease outcome, as indicated through the 
RCI and ACI.
Direct healthcare costs attributable 
to the unequal distribution of 
overweight and obesity
The estimated annual direct healthcare cost 
per person for women and men aged 20 to 
84 years with normal weight, overweight 
and obesity in 2016 was AU$1,706 ($1,488, 
$1,926), $2,026 ($1,842, $2,210) and $2,634 
($2,389, $2,878), respectively. These costs 
modelled across the 2016 Australian 
population equated to $18,325.2 million for 
women and $18,431.2 million for men. 
We found that an estimated $636.5 million 
($628.2, $644.0) and $421.7 million ($395.5, 
$447.2) in direct healthcare spending 
for women and men aged 20 to 84 years 
in 2016 – $1.06 billion ($1.02, 1.09) in 
total – was potentially attributable to the 
socioeconomic gradient in overweight and 
obesity. Hence, approximately 3.4% and 2.5% 
of modelled direct healthcare spending for 
women and men could be attributed to the 




This was the first study to estimate the direct 
healthcare costs associated with the unequal 
distribution of overweight and obesity across 
the socioeconomic spectrum. An estimated 
$1.06 billion (95%CI $1.02, 1.09) in direct 
healthcare costs can be attributed to the 
socioeconomic gradient in overweight and 
obesity among Australian women and men 
in 2016, which is approximately 2.9% of total 
spending. 
Literature comparison
Our results for the lowest SEIFA quintile 
are comparable with results for the lowest 
education group from a previous study 
Gearon et al.
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model is robust and allows for a more precise 
estimation of the disease burden associated 
with overweight and obesity. 
Finally, we derived RRs from the most recent 
and/or most comprehensive meta-analysis or 
pooled cohort study. Studies included 15,700 
to 264,400 events, and most estimates were 
‘adequately adjusted’ (adjusted for age, sex 
and smoking status only, and not variables 
on the causal pathway). Estimates for type 2 
diabetes,3 colorectal cancer,28 kidney cancer,29 
endometrial cancer30 and post-menopausal 
breast cancer31 incidence and mortality were 
derived from meta-analyses, which included 
studies with different levels of adjustment. 
These ranged from minimally adjusted 
studies that controlled for age and sex only, 
through to studies that were adjusted for a 
wider suite of potential confounders. While 
adjusting for a wide suite of confounders may 
result in an underestimated RR,27 the impact 
of including such studies on the final estimate 
was minimal for the kidney cancer29 and 
colorectal cancer28 estimates. 
The first limitation of our study is that 
the model relies on historic data inputs 
– including the number of deaths and 
incident cases of disease, the prevalence of 
overweight and obesity, and the relationship 
between overweight and obesity with disease 
outcomes. Additionally, the model links the 
estimated 2016 overweight and obesity 
exposure levels to estimated 2016 deaths 
and incident cases of disease. Consequently, 
our model will be affected by time trends in 
both overweight and obesity and all disease 
outcomes of interest. As the rate of change in 
obesity, disease and mortality trends over the 
period of input data collection to 2016 is likely 
to be small, any such differences are likely to 
minimally affect modelled estimates.
Secondly, we apply the SEIFA-patterning of 
all disease outcomes and all-cause mortality 
for the total population to our analytic 
population of 20–84-year-olds. As most 
outcomes occur in this age group, the effect 
of this assumption is likely to be minimal.
Thirdly, we included individuals with 
underweight (BMI <18.5 kgm-2) in the normal 
weight group, despite their increased risk 
of ill-health relative to normal weight. This 
was for two reasons: 1) the prevalence of 
underweight within the 2014 National Health 
Survey was too low (1.9% and 0.8% for 
women and men, respectively) to estimate 
the prevalence of underweight across SEIFA 
quintiles; 2) including individuals with 
underweight in the normal weight category 
Notes:
RCI: Relative Concentration Index; ACI: Absolute Concentration Index; I: Incidence; M: Mortality; 
A) Relative concentration index associated with the observed and counterfactual distributions of all disease outcomes. 
B) Absolute concentration index associated with the observed and counterfactual distributions of all disease outcomes. 
Figure 2B is presented across two panels to account for the differing scale of the ACI for all-cause mortality and type 2 diabetes compared to all other disease 
outcomes. 
Figure 2: Relative and absolute concentration indices associated with the observed and counterfactual 
distributions of all disease outcomes for women and men.
(rather than excluding them from analyses) 
ensured that the total number of individuals 
modelled remained constant across the 
observed and counterfactual scenarios. As 
the prevalence of underweight is so low, the 
effect of their inclusion in the normal weight 
category is likely to be minimal. 
Fourthly, our endometrial cancer incidence 
and prevalence data was calculated as 95% 
of all uterine cancers.25 This assumption 
does not affect the endometrial cancer PAF 
estimate or estimated total number of cases 
and deaths for the total population, but the 
number of cases and deaths for each SEIFA 
quintile, and the modelled RCI and ACI, may 
be affected.
Fifthly, while all RRs used were from the most 
recently available or most comprehensive 
meta-analysis or multi-cohort study (as 
described above), they remain an estimation 
of what we would expect to see in our 
analytic population of Australian adults 
aged 20 to 84 years. A number of factors 
contribute to potential variation from an RR. 
Burden of inequalities in overweight obesity
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Table 2: Proportion and number of cases and deaths for specific obesity sequelae attributable to socioeconomic differences in BMI according to SEIFA for Australian women and 
men aged 20 to 84.
SEIFA 1 SEIFA 2 SEIFA 3 SEIFA 4 Total*
% or # (estimate range) % or # (estimate range) % or # (estimate range) % or # (estimate range) % or # (estimate range)
All-cause mortality
W&M % 6 (6, 6) 4 (4, 4) 4 (4, 5) 2 (2, 2) 4 (4, 4)
# I 1,387 (1,340, 1,444) 934 (901, 972) 834 (804, 867) 408 (392, 423) 3,562 (3,436, 3,706)
W % 6 (6, 6) 5 (5, 5) 4 (4, 5) 3 (3, 3) 4 (4, 4)
# I 572 (550, 593) 419 (403, 435) 337 (323, 349) 207 (198, 215) 1,535 (1,474, 1,592)
M % 6 (6, 6) 4 (4, 4) 4 (4, 5) 2 (2, 2) 4 (3, 4)
# I 815 (790, 850) 515 (498, 537) 497 (481, 518) 201 (193, 209) 2,027 (1,962, 2,115)
Incident type 2 diabetes
W&M % 19 (17, 20) 14 (13, 15) 15 (14, 16) 9 (8, 10) 13 (11, 13)
# I 6,573 (6,012, 6,993) 3,700 (3,367, 3,955) 3,510 (3,149, 3,779) 1,867 (1,652, 2,029) 15,650 (14,179, 16,756)
W % 22 (19, 24) 17 (15, 19) 17 (15, 19) 13 (11, 14) 16 (13, 17)
# I 3,471 (3,025, 3,802) 1,832 (1,586, 2,018) 2,145 (1,843, 2,367) 1,154 (982, 1,281) 8,602 (7,437, 9,468)
M % 17 (16, 17) 12 (11, 12) 13 (12, 13) 6 (5, 6) 10 (10, 10)
# I 3,102 (2,986, 3,191) 1,868 (1,781, 1,937) 1,365 (1,306, 1,412) 713 (670, 748) 7,048 (6,742, 7,288)
Ischaemic heart disease mortality
W&M % 5 (4, 6) 4 (3, 4) 4 (3, 5) 2 (2, 3) 3 (2, 4)
# D 131 (103, 159) 88 (67, 108) 80 (61, 98) 35 (25, 45) 333 (257, 409)
W % 6 (4, 8) 4 (3, 6) 4 (3, 6) 3 (2, 4) 4 (3, 5)
# D 47 (33, 59) 34 (24, 43) 28 (20, 37) 17 (12, 23) 126 (88, 162)
M % 5 (4, 5) 3 (3, 4) 3 (3, 4) 2 (1, 2) 3 (2, 3)
# D 84 (70, 99) 54 (44, 65) 51 (42, 61) 18 (14, 22) 207 (169, 247)
Cerebrovascular disease mortality
W&M % 5 (4, 5) 3 (3, 4) 3 (3, 4) 2 (2, 2) 3 (2, 3)
# D 51 (41, 60) 36 (29, 43) 32 (26, 38) 15 (12, 19) 134 (108, 160)
W % 5 (4, 6) 4 (3, 4) 4 (3, 4) 3 (2, 3) 3 (2, 4)
# D 26 (21, 31) 20 (16, 24) 16 (13, 20) 10 (8, 12) 72 (57, 87)
M % 4 (4, 5) 3 (2, 3) 3 (3, 4) 1 (1, 2) 3 (2, 3)
# D 25 (21, 29) 16 (13, 19) 16 (13, 18) 5 (4, 6) 62 (51, 73)
Colorectal cancer incidence and mortality
W&M % 3 (2, 3) 2 (1, 2) 2 (1, 3) 1 (1, 1) 2 (1, 2)
# I 79 (57, 99) 57 (40, 74) 56 (39, 72) 26 (15, 36) 219 (150, 281)
# D 21 (15, 26) 14 (10, 18) 14 (10, 18) 6 (4, 8) 55 (38, 70)
W % 1 (0, 2) 1 (0, 2) 1 (0, 2) 1 (0, 1) 1 (0, 1)
# I 16 (4, 29) 12 (3, 22) 12 (2, 21) 8 (1, 15) 48 (11, 87)
# D 4 (1, 7) 3 (1, 5) 3 (0, 5) 2 (0, 3) 11 (3, 20)
M % 4 (3, 4) 3 (2, 3) 3 (2, 3) 1 (1, 2) 2 (2, 3)
# I 63 (53, 70) 45 (36, 52) 45 (37, 51) 18 (14, 21) 170 (139, 195)
# D 17 (14, 19) 11 (9, 13) 12 (9, 13) 4 (3, 5) 44 (36, 50)
Kidney cancer incidence and mortality
M % 4 (3, 6) 3 (2, 4) 3 (2, 4) 1 (1, 2) 2 (2, 3)
# I 17 (12, 23) 13 (9, 17) 13 (9, 17) 5 (3, 7) 47 (33, 64)
# D 5 (3, 6) 3 (2, 5) 3 (2, 5) 1 (1, 2) 12 (9, 17)
Endometrial cancer incidence and morality
W % 12 (10, 13) 9 (8, 10) 9 (7, 10) 6 (5, 7) 7 (6, 8)
# I 60 (53, 65) 48 (42, 52) 42 (36, 46) 29 (25, 33) 178 (156, 196)
# D 12 (10, 13) 9 (8, 10) 9 (7, 10) 6 (5, 7) 7 (7, 8)
Post-menopausal breast cancer incidence and mortality (Aged 50 to <85 years)
W % 2 (1, 3) 2 (1, 2) 2 (1, 3) 2 (1, 2) 1 (1, 2)
# I 57 (30, 85) 43 (22, 64) 47 (25, 70) 40 (21, 60) 187 (98, 280)
# D 10 (5, 15) 7 (4, 11) 8 (4, 11) 6 (3, 9) 31 (16, 46)
Notes:
SEIFA, Socioeconomic index for areas, ‘index of relative socioeconomic disadvantage’; W&M: women and men; W: women; M: men; 
* Total population estimates calculated as the sum of incident cases or deaths for all SEIFA groups combined; estimate range, as calculated using the 95% CI of the RR for each estimate; 
%, proportion of incident cases or deaths potentially attributable to socioeconomic differences in overweight and obesity; 
#I Number of incident cases; 
#D Number of deaths. 
Because our model uses the overweight and obesity prevalence of SEIFA 5 as the reference point, we modelled no reduction in diseases for this quintile. 
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These primarily relate to differences in the 
population from which the RR was derived 
and the analytic population, such as the age 
range, ethnicity and population prevalence 
of confounders, as well as controls and 
adjustments made to calculate the RR. Our 
estimate for all-cause mortality43 restricted 
analyses to ‘never smokers’ free from chronic 
disease in order to attain an unbiased 
estimate for the risk associated with obesity 
and overweight relative to normal weight.32 
This approach accounts for the competing 
risk of death among individuals with pre-
existing disease and who are current or 
former smokers, and is therefore less likely to 
be biased;48 however, the number of deaths 
expected to be avoided if the prevalence 
of overweight and obesity were changed is 
likely to be overestimated.48 
Finally, the annual direct healthcare cost 
estimates for this study come from a cohort 
of 6,140 Australian adults aged 25 to 84 
years over the period 2000 to 2004–05. The 
differential retention of individuals with a 
more favourable health status in longitudinal 
studies means these cost estimates are likely 
to be an underestimation of the costs for the 
total population. 
Implications and conclusions
Our study was the first to estimate the direct 
healthcare cost associated with the unequal 
distribution of overweight and obesity across 
the socioeconomic spectrum. An important 
assumption of our study is that the direct 
healthcare costs associated with normal 
weight, overweight and obesity are constant 
across SEIFA quintiles. Contemporary 
estimates of the direct healthcare costs 
associated with overweight and obesity for 
each socioeconomic group will be required 
to refine this estimate and strengthen the 
conclusions of the current study. 
We modelled the disease burden and direct 
healthcare costs associated with the unequal 
distribution of overweight and obesity 
to better understand the importance of 
considering equity in all overweight and 
obesity treatment and prevention initiatives. 
Our results clearly demonstrate that reducing 
the socioeconomic gradient in obesity can 
reduce the socioeconomic gradient in the 
incidence and death for a range of diseases 
and reduce healthcare spending. Achieving 
equitable population obesity prevention 
will require a suite of obesity prevention, 
management and treatments, where the 
health benefits are proportionate to the level 
of disadvantage. However, our RCI and ACI 
findings indicate that even after accounting 
for the impact of the socioeconomic gradient 
in overweight and obesity, an observed 
socioeconomic gradient in all diseases 
modelled remains. Addressing these 
inequalities in ill-health is therefore likely to 
require action on other risk factors for non-
communicable diseases, such as smoking, 
as well as the upstream environmental 
drivers of disease49 and action on the social 
determinants of health.50 
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